TNGX - CIK 0001819133
The table below shows Tango Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $157.83M | $58.34M | $39.27M | $58.43M | $53.15M | $51.57M |
| Short-term investments | $222.01M | $94.47M | $141.51M | $158.29M | $240.13M | $270.55M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $392.33M |
| $163.78M |
| $190.10M |
| $224.93M |
| $300.81M |
| $328.41M |
| Property, plant & equipment | $6.38M | $7.35M | $7.79M | $7.54M | $8.59M | $9.10M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $435.79M | $210.14M | $237.89M | $274.31M | $352.42M | $381.45M |
| Accounts payable | $2.43M | $2.23M | $2.61M | $3.24M | $4.11M | $1.06M |
| Total current liabilities | $14.33M | $18.44M | $40.02M | $35.92M | $37.58M | $43.87M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $44.29M | $50.10M | $102.94M | $107.55M | $123.25M | $133.78M |
| Retained earnings | -$648.67M | -$564.40M | -$580.29M | -$541.43M | -$463.89M | -$434.72M |
| Total equity | $391.51M | $160.03M | $134.95M | $166.76M | $229.17M | $247.67M |